We Just Had An Epiphany
Tag: Intismeran
🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued
Moderna has already doubled from its 2025 lows, yet we believe the story is still in its early chapters. Science Day confirmed that Moderna is becoming far more than a vaccine company—it's building one of biotechnology's most ambitious programmable medicine platforms.